RightFit Trial Directory

Lung Cancer clinical trials in Rochester, MN

24 recruiting lung cancer studies with a site in Rochester, MN.

All trials in Rochester, MN · All Lung Cancer trials

RecruitingPhase 3NCT04267848

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Sponsor: National Cancer Institute (NCI)

Aitkin, MN · Bemidji, MN · Brainerd, MN · +1147 more sites

RecruitingPhase 1 / Phase 2NCT06810544

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

Sponsor: Tango Therapeutics, Inc.

Rochester, MN · +14 more sites

RecruitingPhase 2NCT07492680

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Sponsor: Bristol-Myers Squibb

Rochester, MN · +13 more sites

RecruitingPhase 1 / Phase 2NCT06362252

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

Sponsor: Daiichi Sankyo

Minneapolis, MN · Rochester, MN · +24 more sites

RecruitingPhase 1 / Phase 2NCT06996782

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Sponsor: AstraZeneca

Rochester, MN · +9 more sites

RecruitingPhase 1NCT07277413

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

Sponsor: IDEAYA Biosciences

Rochester, MN · +22 more sites

RecruitingPhase 2NCT06693336

An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer

Sponsor: ToLymph Inc.

Rochester, MN

RecruitingPhase 2 / Phase 3NCT07063745

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Sponsor: Bristol-Myers Squibb

Rochester, MN · +43 more sites

RecruitingPhase not listedNCT05059444

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Sponsor: Guardant Health, Inc.

Rochester, MN · +32 more sites

RecruitingPhase not listedNCT06674811

Biomarkers of Resiliency In Childhood Cancer Surgery

Sponsor: Mayo Clinic

Rochester, MN

RecruitingPhase not listedNCT06482073

Molecular Analysis of Suspected or High-Risk Lung Cancer to Drive Individualized Care

Sponsor: Mayo Clinic

Rochester, MN

RecruitingPhase 1NCT05245500

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Sponsor: Bristol-Myers Squibb

Rochester, MN · +24 more sites

RecruitingPhase 1NCT07027514

A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

Sponsor: Ankyra Therapeutics, Inc

Rochester, MN · +10 more sites

RecruitingPhase 1 / Phase 2NCT06892548

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

Sponsor: BioNTech SE

Rochester, MN · +16 more sites

RecruitingPhase 1 / Phase 2NCT06706076

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

Sponsor: BlossomHill Therapeutics

Rochester, MN · +23 more sites

RecruitingPhase 1NCT05433142

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

Sponsor: Xencor, Inc.

Rochester, MN · +19 more sites

RecruitingPhase 1NCT06562192

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

Sponsor: Novartis Pharmaceuticals

Rochester, MN · +8 more sites

RecruitingPhase 3NCT06686771

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

Sponsor: Canadian Cancer Trials Group

Duluth, MN · Rochester, MN · Saint Cloud, MN · +68 more sites

RecruitingPhase not listedNCT06075524

Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types

Sponsor: Mayo Clinic

Rochester, MN

RecruitingPhase 1 / Phase 2NCT06051695

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Sponsor: A2 Biotherapeutics Inc.

Rochester, MN · +11 more sites

RecruitingPhase 2 / Phase 3NCT03851445

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Sponsor: SWOG Cancer Research Network

Aitkin, MN · Baxter, MN · Bemidji, MN · +1226 more sites

RecruitingPhase 3NCT02468024

JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

Sponsor: University of Texas Southwestern Medical Center

Rochester, MN · +39 more sites

RecruitingPhase 1NCT06712810

Q702 for the Treatment of Patients With Hematologic Malignancies

Sponsor: Mayo Clinic

Rochester, MN · +1 more sites

RecruitingPhase 1 / Phase 2NCT06682793

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Sponsor: A2 Biotherapeutics Inc.

Rochester, MN · +9 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.